IQVIA (NYSE:IQV) Shares Acquired Sen. Markwayne Mullin

Senator Markwayne Mullin (R-Oklahoma) recently bought shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on January 16th, the Senator disclosed that they had bought between $15,001 and $50,000 in IQVIA stock on December 29th.

Senator Markwayne Mullin also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Deere & Company (NYSE:DE) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Hilton Worldwide (NYSE:HLT) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of RTX (NYSE:RTX) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of CocaCola (NYSE:KO) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Elevance Health (NYSE:ELV) on 12/29/2025.
• Purchased $1,001 – $15,000 in shares of American Express (NYSE:AXP) on 12/29/2025.
• Purchased $100,001 – $250,000 in shares of Amazon.com (NASDAQ:AMZN) on 12/29/2025.
• Purchased $50,001 – $100,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Boston Scientific (NYSE:BSX) on 12/29/2025.

IQVIA Price Performance

NYSE:IQV traded down $3.25 during mid-day trading on Friday, reaching $238.03. The stock had a trading volume of 1,350,702 shares, compared to its average volume of 1,068,363. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The stock has a market capitalization of $40.54 billion, a PE ratio of 32.65, a P/E/G ratio of 2.42 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The stock has a 50-day simple moving average of $227.30 and a two-hundred day simple moving average of $203.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter last year, the company posted $2.84 EPS. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Mizuho set a $266.00 price objective on shares of IQVIA in a research report on Friday, January 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Morgan Stanley increased their price target on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Barclays set a $230.00 price objective on IQVIA in a research report on Monday, December 15th. Finally, Robert W. Baird set a $258.00 target price on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $249.19.

Hedge Funds Weigh In On IQVIA

Hedge funds have recently bought and sold shares of the company. Physician Wealth Advisors Inc. increased its stake in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the last quarter. Westside Investment Management Inc. boosted its holdings in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new position in IQVIA during the third quarter valued at about $30,000. Atlantic Union Bankshares Corp bought a new stake in IQVIA in the third quarter worth about $36,000. Finally, Root Financial Partners LLC purchased a new stake in shares of IQVIA during the 3rd quarter worth approximately $43,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.60% of the company’s stock.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.